Review Article
Intravenous Fosfomycin: An Assessment of Its Potential for Use in the Treatment of Systemic Infections in Canada
Table 4
Comparative clinical studies describing outcomes for patients receiving intravenous fosfomycin in combination with a second antimicrobial agent.
| Trial design (reference) Infection type () | Treatment regimens and outcomes | Pathogens |
| Open label nonrandomized [55] Septicemia (32), osteoarthritis (1), meningitis (1), and pulmonary infection (1) | Group 1: 17 patients fosfomycin (237.1 mg/kg daily IV)/penicillin Cure: 16/17 (94.1%) Group 2: 18 patients gentamicin/penicillin Cure: 14/18 (77.7%) | MSSA |
| Prospective randomized [56] Ventilator-associated pneumonia (22) and pneumonia (10) | Group 1: 17 patients fosfomycin (12 g daily IV)/ampicillin Cure: 10/17 (58.8%); improvement: 6/17 (35.2%) Group 2: 15 patients gentamicin/ampicillin Cure: 7/15 (46.6%); improvement: 5/15 (33.3%) | E. coli, coagulase-positive staphylococci, P. aeruginosa, and Klebsiella |
|
|